• Inborn errors of metabolism

Strensiq Generic Name & Formulations

General Description

Asfotase alfa 18mg/0.45mL, 28mg/0.7mL, 40mg/mL, 80mg/0.8mL; soln for SC inj; preservative-free.

Pharmacological Class

Tissue nonspecific alkaline phosphatase.

How Supplied

Single-use vials—1, 12

Generic Availability


Strensiq Indications


Treatment of perinatal/infantile- and juvenile-onset hypophosphatasia.

Strensiq Dosage and Administration


Not applicable.


See full labeling. Give by SC inj in the abdomen, thigh, deltoid, or buttocks; rotate inj sites. 6mg/kg per week given as 2mg/kg 3 times weekly or 1mg/kg 6 times weekly. Perinatal/infantile-onset: if ineffective, may increase dose up to 9mg/kg per week given as 3mg/kg 3 times weekly. <40kg: do not use 80mg/0.8mL vial.

Strensiq Contraindications

Not Applicable

Strensiq Boxed Warnings

Not Applicable

Strensiq Warnings/Precautions


Do not administer to areas that are reddened, inflamed, or swollen. Discontinue if severe hypersensitivity reaction occurs; monitor for reoccurrence if repeat treatment. Perform ophthalmic exams and renal ultrasounds at baseline and periodically during treatment. Monitor for ectopic calcifications and changes in vision or renal function. Possible immune-mediated clinical effects. Pregnancy. Nursing mothers.

Strensiq Pharmacokinetics

See Literature

Strensiq Interactions


May cause erroneous results in lab assays that utilize alkaline phosphatase (ALP)-conjugated test system. Do not rely on serum ALP measurements for clinical decision making due to expected high levels.

Strensiq Adverse Reactions

Adverse Reactions

Inj site reactions, lipodystrophy, ectopic calcifications, hypersensitivity reactions.

Strensiq Clinical Trials

See Literature

Strensiq Note

Not Applicable

Strensiq Patient Counseling

See Literature